Cardiology Pharmaceuticals

SPORT: Statins Obliterate OTC Heart Supplements

Rosuvastatin 5 mg daily lowered LDL-C levels more than fish oil, cinnamon, garlic, turmeric, red yeast rice, and placebo in those with increased 10-year risk for ASCVD, according to a recent study presented at AHA 2022. 

Over-the-counter heart supplements claim to fight cholesterol and promote heart health, and many Americans subscribe to the hype. The study’s lead author Luke Laffin, MD explained that 75% of Americans take at least one dietary supplement, and 18% percent take a supplement to promote heart function. 

Laffin’s findings challenge the multibillion dollar industry. 

In the study, researchers looked at data from 200 adults with no history of cardiovascular disease, but who had a 5-20% risk of developing ASCVD within 10 years. Researchers randomly assigned participants to one of eight groups: placebo, rosuvastatin (5 mg), fish oil (2400 mg), cinnamon (2400 mg), garlic (with 5000 mcg of allicin), turmeric (3500 mg), plant sterols (1600 mg), and red yeast rice (2400 mg). 

LDL-C levels decreased in the following groups at 28 days: 

  • Rosuvastatin: -38%
  • Placebo: -2.6%
  • Fish oil: -3.4%
  • Turmeric: -1.3% 
  • Plant sterols: -4.37%
  • Red yeast rice: -6.5%

LDL-C levels actually increased in people taking these supplements: 

  • Cinnamon: +0.4%
  • Garlic: +5.1%

The Takeaway 

Six widely used dietary supplements promoted for improving heart health – including brands of fish oil, cinnamon, garlic, and turmeric – were not as effective as rosuvastatin at lowering LDL cholesterol. Statins are still the cholesterol kingpin. As cardiologists have been saying for decades (and as they made clear on twitter), supplements cannot take the place of an effective statin. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square